A3GALT2: A Potential Drug Target Or Biomarker (G127550)

Target Name: A3GALT2

NCBI ID: G127550

A3GALT2

A3GALT2: A Potential Drug Target Or Biomarker

A3GALT2 (A3LT2_HUMAN), a protein that belongs to the A3GALT2 family, is a protein that is expressed in various tissues of the human body. The A3GALT2 gene has been identified and its function is being studied extensively. This protein has been shown to play a significant role in various physiological processes in the body, including cell signaling, inflammation, and metabolism. As a result, A3GALT2 has been identified as a potential drug target or biomarker.

A3GALT2 is a protein that is characterized by its unique structure and biological function. It is a 21-kDa protein that consists of 156 amino acid residues. The protein has a distinct N-terminal and C-terminal region, each of which is rich in conserved domains. The N-terminal region of A3GALT2 contains a unique N-tail that is composed of a short amino acid sequence and a long non-coding region that is involved in protein-protein interactions. The C-terminal region of A3GALT2 contains a unique C-tail that is composed of a long amino acid sequence that is involved in protein-protein interactions and a short non-coding region that is involved in protein-DNA interactions.

One of the most significant functions of A3GALT2 is its role in cell signaling. A3GALT2 is involved in a variety of signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, angiogenesis, and inflammation.

In addition to its role in cell signaling, A3GALT2 is also involved in the regulation of inflammation. A3GALT2 has been shown to play a significant role in the regulation of inflammation and its expression is often increased in diseases associated with inflammation, such as cancer, autoimmune diseases, and obesity.

Furthermore, A3GALT2 is also involved in the regulation of metabolism. The A3GALT2 gene has been shown to play a significant role in the regulation of glucose metabolism and its expression is often increased in individuals with diabetes.

A3GALT2 has also been shown to play a significant role in the development and progression of various diseases, including cancer. A3GALT2 has been shown to be involved in the regulation of cell cycle progression and its expression is often increased in various types of cancer.

In conclusion, A3GALT2 is a protein that is characterized by its unique structure and biological function. It is involved in a variety of cellular processes, including cell signaling, inflammation, and metabolism, and has been shown to play a significant role in the development and progression of various diseases. As a result, A3GALT2 has been identified as a potential drug target or biomarker and further research is being conducted to determine its potential therapeutic uses.

Protein Name: Alpha 1,3-galactosyltransferase 2

Functions: Synthesizes the galactose-alpha(1,3)-galactose group on the glycosphingolipid isoglobotrihexosylceramide or isogloboside 3 (iGb3) by catalyzing the transfer of galactose from UDP-Galactose to its acceptor molecule Gal-beta-1,4-Glc-ceramide. Can also catalyze the addition of galactose to iGb3 itself to form polygalactose structures

The "A3GALT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about A3GALT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets